A 37-year old woman was told she had less than a year to live after doctors said she had incurable breast cancer. Nicola ...
AstraZeneca has built its leading presence in the pharma and biotech industry on patent-protected drugs and a developing pipeline that support a wide moat. The strong replenishment of new drugs sets ...
New study results presented at the European Lung Cancer Congress (ELCC) 2025, 26 to 29 March, demonstrate the role of AstraZeneca’s Tagrisso (osimertinib), as monotherapy and as the backbone for novel ...
Specifically, Enhertu (trastuzumab deruxtecan ... Offsetting the increased efficacy is a risk of severe side effects, including interstitial lung disease (ILD), that may be more significant ...
AstraZeneca has agreed to acquire Belgian in vivo cell therapy biotech EsoBiotec, strengthening its position in the emerging ...
Nicola Heart believed that holding her newborn babies as they died would be the most difficult experience of her life. That ...
Because it can have potential side-effects such as bleeding in the stomach ... Her only hope was a new toxic cancer drug called Enhertu – but it was found to be too expensive for the NHS ...
Dr. Debu Tripathy breaks down the FDA approval of Enhertu in unresectable or metastatic HR-positive ... including those focused on patient-reported outcomes and side effect management, among others.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback